Furthermore, combining ICIs with adoptive T-cell therapies, like CAR-T cells engineered to target HER2, represents an innovative approach that may further improve outcomes by directly targeting tumor cells while also modulating the immune response. Here, ERBB2 is linked to neoplasm.